Fimasartan.
Fimasartan (BR-A-657; BR-A-657-K; Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT(1) receptor subtype, is being developed by Boryung Pharmaceutical as an oral treatment for hypertension. Fimasartan has been approved for use in patients with hypertension in South Korea and has been evaluated in three phase III clinical trials (i.e. NCT00922480, NCT01135212, and NCT01258673). This review discusses the development history and scientific profile of this new compound. This summary has been extracted from Wolters Kluwer's Adis R&D Insight drug pipeline database. Adis R&D Insight tracks and evaluates drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.